mRNA-1345
Phase 2Active 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus
Conditions
Respiratory Syncytial Virus
Trial Timeline
Nov 15, 2023 → May 27, 2026
NCT ID
NCT06143046About mRNA-1345
mRNA-1345 is a phase 2 stage product being developed by Moderna for Respiratory Syncytial Virus. The current trial status is active. This product is registered under clinical trial identifier NCT06143046. Target conditions include Respiratory Syncytial Virus.
What happened to similar drugs?
10 of 20 similar drugs in Respiratory Syncytial Virus were approved
Approved (10) Terminated (3) Active (9)
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07117487 | Phase 3 | Active |
| NCT06143046 | Phase 2 | Active |
| NCT06097299 | Phase 2 | Completed |
| NCT06067230 | Phase 3 | Active |
| NCT06060457 | Phase 3 | Completed |
| NCT05743881 | Phase 1 | Active |
| NCT05572658 | Preclinical | Completed |
| NCT05330975 | Phase 3 | Completed |
| NCT05127434 | Phase 3 | Completed |
| NCT04528719 | Phase 1 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1273 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| mRNA-1345 | Moderna | Phase 2 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Preclinical | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 3 | 0 |
| mRNA-1345 | Moderna | Phase 1 | 0 |
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 44 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 30 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 19 |
| YMC026 + Placebo | Yuhan | Approved | 43 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 35 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 32 |
| S-337395 + Placebo | Shionogi | Phase 2 | 42 |
| Sivelestat | Eli Lilly | Phase 1/2 | 32 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 35 |